Literature DB >> 12034985

Eclipse: does it live up to its health claims?

J Slade1, Gregory N Connolly, D Lymperis.   

Abstract

OBJECTIVE: To examine the plausibility of health claims for Eclipse, a novel smoking article being marketed by the RJ Reynolds Tobacco Company (RJR) as potentially reducing the risk of cancer and other diseases compared to conventional cigarettes. DATA SOURCES: A company product website (www.eclipse.rjrt.com) summarising scientific studies of various versions of Eclipse, and the published review of these studies by an expert panel convened by RJR, an independent study comparing the smoke yields of major carcinogens from Eclipse and two low yield "ultralight" brands (Now and Carlton), and an analysis of the levels of these compounds in Eclipse and Premier (its predecessor) over time. ANALYSIS: The overall doses and effects of toxins in the aerosol from Eclipse are smaller than those from most conventional cigarettes on a per mg basis. However, two tests that compared Eclipse on a per cigarette basis revealed that Eclipse was as or more toxic than an ultralight cigarette. Studies show that consumers smoke Eclipse (like they do cigarettes) at puff volumes and puff frequencies far higher than those used for the Federal Trade Commission (FTC) test. RJR's test results, which are based on aerosols generated under FTC conditions, may not reflect actual human dosing, since the operating temperature of Eclipse is highly dependent on these puffing parameters. Even under FTC/International Organization for Standardization (ISO) standard measures, Eclipse smoke carcinogen yields were higher than Now, but similar to Carlton. The yields of carcinogens from Premier and different versions of Eclipse have increased over time. Furthermore, the human studies reviewed by the RJR expert panel do not offer compelling evidence of reduced harm, as they have not been conducted in smokers who have adopted Eclipse.
CONCLUSION: There is as yet unsatisfactory evidence that Eclipse is less harmful than conventional cigarettes. Eclipse appears to be at least as toxic as some commercially available cigarette brands. Consumers may be misled by RJR's health claims into believing that Eclipse is a safer alternative to conventional cigarettes, underscoring the need for regulatory intervention.

Entities:  

Mesh:

Year:  2002        PMID: 12034985      PMCID: PMC1766079          DOI: 10.1136/tc.11.suppl_2.ii64

Source DB:  PubMed          Journal:  Tob Control        ISSN: 0964-4563            Impact factor:   7.552


  4 in total

1.  A comparison of the yields of tar, nicotine, and carbon monoxide of 36 brands of Canadian cigarettes tested under three conditions.

Authors:  W S Rickert; J C Robinson; J C Young; N E Collishaw; D F Bray
Journal:  Prev Med       Date:  1983-09       Impact factor: 4.018

2.  Glass fiber contamination of cigarette filters: an additional health risk to the smoker?

Authors:  J L Pauly; H J Lee; E L Hurley; K M Cummings; J D Lesses; R J Streck
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1998-11       Impact factor: 4.254

3.  A further study of FTC yield and nicotine absorption in smokers.

Authors:  G D Byrd; R A Davis; W S Caldwell; J H Robinson; J D deBethizy
Journal:  Psychopharmacology (Berl)       Date:  1998-10       Impact factor: 4.530

Review 4.  The tobacco epidemic: lessons from history.

Authors:  J Slade
Journal:  J Psychoactive Drugs       Date:  1989 Jul-Sep
  4 in total
  15 in total

1.  A Premiere example of the illusion of harm reduction cigarettes in the 1990s.

Authors:  R W Pollay; T Dewhirst
Journal:  Tob Control       Date:  2003-09       Impact factor: 7.552

2.  Preliminary investigation of the advertising and availability of PREPs, the new "safe" tobacco products.

Authors:  Norval Hickman; Elizabeth A Klonoff; Hope Landrine; Kennon Kashima; Bina Parekh; Senaida Fernandez; Kamala Thomas; Catherine Brouillard; Michele Zolezzi; Jennifer Jensen; Zorahna Weslowski
Journal:  J Behav Med       Date:  2004-08

3.  New tobacco products: do smokers like them?

Authors:  R S Caraballo; L L Pederson; N Gupta
Journal:  Tob Control       Date:  2006-02       Impact factor: 7.552

4.  Impact of corrective health information on consumers' perceptions of "reduced exposure" tobacco products.

Authors:  Lois Biener; Karen Bogen; Gregory Connolly
Journal:  Tob Control       Date:  2007-10       Impact factor: 7.552

Review 5.  Postmarketing surveillance for "modified-risk" tobacco products.

Authors:  Richard J O'Connor
Journal:  Nicotine Tob Res       Date:  2011-01-20       Impact factor: 4.244

6.  Cigarette company trade secrets are not secret: an analysis of reverse engineering reports in internal tobacco industry documents released as a result of litigation.

Authors:  Clayton Velicer; Lauren K Lempert; Stanton Glantz
Journal:  Tob Control       Date:  2014-06-11       Impact factor: 7.552

Review 7.  Tobacco industry litigation position on addiction: continued dependence on past views.

Authors:  Jack E Henningfield; Christine A Rose; Mitch Zeller
Journal:  Tob Control       Date:  2006-12       Impact factor: 7.552

Review 8.  Potential reduced exposure products (PREPs) in industry trial testimony.

Authors:  Geoffrey Ferris Wayne
Journal:  Tob Control       Date:  2006-12       Impact factor: 7.552

Review 9.  Reconciling human smoking behavior and machine smoking patterns: implications for understanding smoking behavior and the impact on laboratory studies.

Authors:  Catalin Marian; Richard J O'Connor; Mirjana V Djordjevic; Vaughan W Rees; Dorothy K Hatsukami; Peter G Shields
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-12       Impact factor: 4.254

Review 10.  Surveillance methods for identifying, characterizing, and monitoring tobacco products: potential reduced exposure products as an example.

Authors:  Richard J O'Connor; K Michael Cummings; Vaughan W Rees; Gregory N Connolly; Kaila J Norton; David Sweanor; Mark Parascandola; Dorothy K Hatsukami; Peter G Shields
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-12       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.